Drug Profile
HYB 190
Alternative Names: HYB-190; PKAI-AS 190Latest Information Update: 20 Jan 2023
Price :
$50
*
At a glance
- Originator Idera Pharmaceuticals
- Developer Aceragen
- Class Antineoplastics; Antisense oligonucleotides; Nucleotides
- Mechanism of Action Protein kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Renal cancer